Correlation between Macular Neovascularization (MNV) Type and Druse Type in Neovascular Age-Related Macular Degeneration (AMD) Based on the CONAN Classification
Daniel Rudolf Muth,
Mario Damiano Toro,
Anahita Bajka,
Kamil Jonak,
Roman Rieder,
Myrtha Magdalena Kohler,
Jeanne Martine Gunzinger,
Eric H. Souied,
Michael Engelbert,
K. Bailey Freund,
Sandrine Anne Zweifel
Affiliations
Daniel Rudolf Muth
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Mario Damiano Toro
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Anahita Bajka
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Kamil Jonak
Department of Biomedical Engineering, Lublin University of Technology, 20-618 Lublin, Poland
Roman Rieder
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Myrtha Magdalena Kohler
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Jeanne Martine Gunzinger
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
Eric H. Souied
Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 94000 Creteil, France
Michael Engelbert
Vitreous Retina Macula Consultants of New York, New York, NY 10022, USA
K. Bailey Freund
Vitreous Retina Macula Consultants of New York, New York, NY 10022, USA
Sandrine Anne Zweifel
Department of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland
To investigate associations and predictive factors between macular neovascularization (MNV) lesion variants and drusen types in patients with treatment-naïve neovascular age-related macular degeneration (AMD). Methods: Multimodal imaging was retrospectively reviewed for druse type (soft drusen, subretinal drusenoid deposits (SDDs) or mixed) and MNV type (MNV 1, MNV 2, MNV 1/2 or MNV 3). The Consensus on Neovascular AMD Nomenclature (CONAN) classification was used for characterizing MNV at baseline. Results: One eye of each eligible patient was included (n = 191). Patients with predominant SDDs had an increased adjusted odds ratio (aOR) for MNV 2 (23.4453, p = 0.0025) and any type of MNV 3 (8.7374, p p = 0.0084). Patients with MNV1 showed an aOR for SDDs (0.0357, p p < 0.0001). Conclusions: SDDs represent a common phenotypic characteristic in AMD eyes with treatment-naïve MNV. The aOR for eyes with predominant SDDs to develop MNV 2 and MNV 3 was much higher, possibly due to their location in the subretinal space. The predominant druse type may help to predict which type of MNV will develop during the course of AMD.
